BrainStorm to Announce Fourth Quarter and Fiscal Year 2024 Financial Results and Provide a Corporate Update

Company Overview - BrainStorm Cell Therapeutics Inc. is a leading developer of adult stem cell therapeutics for neurodegenerative diseases, focusing on innovative therapies leveraging both autologous and allogeneic platforms [5] - The company holds exclusive worldwide licensing rights for the NurOwn® technology platform, which produces autologous MSC-NTF cells, designated as Orphan Drug by the FDA and EMA for amyotrophic lateral sclerosis (ALS) [5] - BrainStorm is planning a confirmatory Phase 3b trial in ALS with NurOwn to further evaluate its safety and efficacy [5] Upcoming Conference Call - A conference call and webcast will be held on March 31, 2025, at 8:30 AM Eastern Time to update shareholders on financial results for the fourth quarter and year ended December 31, 2024 [1] - Key executives participating in the call include Chaim Lebovits (President and CEO), Hartoun Hartounian (COO), Bob Dagher (CMO), and Alla Patlis (interim CFO) [2] - Participants can submit questions in advance by March 28, 2025, and the call will include a Q&A session with the investment community [3][2] Clinical Development - The company has completed a Phase 3 trial assessing NurOwn in ALS and is advancing clinical studies of NurOwn in progressive multiple sclerosis (MS), supported by grants from the California Institute for Regenerative Medicine (CIRM) and the National MS Society (NMSS) [5] - BrainStorm's exosome technology, derived from MSC-NTF cells, offers customizable, nano-carrier-based solutions for targeted delivery of bioactive molecules, addressing critical pathways in neurodegenerative and respiratory diseases [5]